CommonSenseTV Get real!

Support the real news!

Our Facebook, Twitter and Telegram

Vaccine victims, you shouldn't spread fake news about that.

Meanwhile 4.576 KILL 199.213 Injuries:

European database of adverse reactions to COVID-19 'vaccines'

Frontnieuws published this message today with the request to share it as much as possible. We do that on CommonSenseTV of course. And we also request our readers to share the message as much as possible. Because the jubilant stories about these experimental syringes we know by now.

 

De European database of reports of suspected reactions to medication, EudraVigilance, keeps track of injuries and deaths after the experimental Covid-19 'vaccines'.

 

Their report to March 20, 2021 lists 4.576 dead and 199.213 injured after injections of four experimental COVID-19 injections:

A subscriber to Health Impact News in Europe has checked the reports for each of the three Covid-19 injections that Frontnieuws is including here, and here is the summary data up to March 13, 2021. This subscriber has volunteered to do so, and it is a lot of work to with injuries and fatalities in a table, as there is no place on the EudraVigilance system where all results are tabulated.

So by the time this data is published, the statistics are already a week old and new statistics are already available.

Here's the summary of the data up to March 20, 2021.

 

Total number of responses for the experimental mRNA vaccine Tozinameran (code BNT162b2, Comirnaty) from BioNTech / Pfizer:

2.906 dead and 111.508 injured up to 20/03/2021

  • 8.286 Blood and lymphatic system disorders incl. 17 deaths
  • 5.094 Cardiac disorders incl. 326 deaths
  • 25 Congenital, familial and genetic disorders incl. 2 deaths
  • 2.947 Ear and labyrinth disorders
  • 54 Endocrine Disorders
  • 3.207 Eye disorders incl. 3 deaths
  • 25.177 Gastrointestinal disorders incl. 144 deaths
  • 78.540 General disorders and administration site conditions incl. 1050 deaths
  • 117 Hepatobiliary disorders incl. 14 deaths
  • 2.148 Immune system disorders incl. 13 deaths
  • 6.662 Infections and infections incl. 302 deaths
  • 2.436 Injury, poisoning and procedural complications incl. 43 deaths
  • 5.087 Investigations incl. 129 deaths
  • 1.726 Metabolic and nutritional disorders incl. 57 deaths
  • 40.753 Musculoskeletal and connective tissue disorders incl. 26 deaths
  • 69 Neoplasms benign, malignant and unspecified (incl cysts and polyps) incl. 3 deaths
  • 49.030 Nervous system disorders incl. 226 deaths
  • 107 Pregnancy, postpartum and perinatal disorders incl. 3 deaths
  • 58 Product Problems
  • 4.150 Psychiatric disorders incl. 39 deaths
  • 592 Renal and urinary disorders incl. 39 deaths
  • 609 Reproductive System and Breast Disorders
  • 9.604 Respiratory, thoracic and mediastinal disorders incl. 340 deaths
  • 11.720 Skin and subcutaneous tissue disorders incl. 21 deaths
  • 262 Social circumstances incl. 6 deaths
  • 79 Surgical and medical procedures incl. 5 deaths
  • 5.401 Vascular disorders incl. 99 deaths

 

Total responses to Moderna's experimental mRNA vaccine mRNA-1273 (CX-024414):

1076 deaths and 7.030 injuries to 20/03/2021

  • 375 Blood and lymphatic system disorders incl. 10 deaths
  • 569 Cardiac disorders incl. 111 deaths
  • 1 Congenital, familial and genetic disorder
  • 133 Ear and labyrinth disorders
  • 9 Endocrine Disorders
  • 211 Eye disorders incl. 2 deaths
  • 1.513 Gastrointestinal disorders incl. 42 deaths
  • 4.961 General disorders and administration site conditions incl. 452 deaths
  • 25 Hepatobiliary disorders
  • 246 Immune system disorders incl. 1 death
  • 601 Infections and infections incl. 60 deaths
  • 277 Injury, poisoning and procedural complications incl. 18 deaths
  • 467 Investigations incl. 37 deaths
  • 204 Metabolic and nutritional disorders incl. 19 deaths
  • 2.036 Musculoskeletal and connective tissue disorders incl. 23 deaths
  • 21 Neoplasms benign, malignant and unspecified (incl cysts and polyps) incl. 3 deaths
  • 2.746 Nervous system disorders incl. 119 deaths
  • 19 Pregnancy, postpartum and perinatal disorders
  • 4 Product Problems
  • 328 Psychiatric disorders incl. 15 deaths
  • 106 Renal and urinary disorders incl. 11 deaths
  • 38 Reproductive system and breast disorders incl. 1 death
  • 929 Respiratory, thoracic and mediastinal disorders incl. 95 deaths
  • 894 Skin and subcutaneous tissue disorders incl. 11 deaths
  • 57 Social circumstances incl. 3 deaths
  • 45 Surgical and medical procedures incl. 4 deaths
  • 444 Vascular disorders incl. 39 deaths

 

Total responses for the experimental vaccine AZD1222 (CHADOX1 NCOV-19) from Oxford / AstraZeneca:

592 deaths and 80.642 injuries up to 20/03/2021

  • 1.867 Blood and lymphatic system disorders incl. 20 deaths
  • 3.163 Cardiac disorders incl. 78 deaths
  • 22 Congenital, familial, and genetic disorders
  • 1.068 Ear and labyrinth disorders
  • 60 Endocrine disorders incl. 1 death
  • 3.007 Eye disorders incl. 1 death
  • 25.649 Gastrointestinal disorders incl. 26 deaths
  • 62.945 General disorders and administration site conditions incl. 244 deaths
  • 66 Hepatobiliary disorders incl. 3 deaths
  • 837 Immune system disorders
  • 4.785 Infections and infections incl. 53 deaths
  • 1.357 Injuries, poisoning and complications from the procedure incl. 4 deaths
  • 3.682 Investigations incl. 6 deaths
  • 3.731 Metabolic and nutritional disorders incl. 6 deaths
  • 34.943 Musculoskeletal and connective tissue disorders incl. 6 deaths
  • 27 Neoplasms benign, malignant and unspecified (incl cysts and polyps) incl. 2 deaths
  • 48.339 Nervous system disorders incl. 59 deaths
  • 36 Pregnancy, postpartum and perinatal disorders
  • 17 Product Problems
  • 4.374 Psychiatric disorders incl. 3 deaths
  • 800 Renal and urinary disorders incl. 8 deaths
  • 462 Reproductive System and Breast Disorders
  • 6.474 Respiratory, thoracic and mediastinal disorders incl. 47 deaths
  • 10.029 Skin and subcutaneous tissue disorders incl. 4 deaths
  • 153 Social circumstances incl. 2 deaths
  • 182 Surgical and medical procedures incl. 5 deaths
  • 2.646 Vascular disorders incl. 14 deaths

 

Total number of responses to Johnson & Johnson's experimental COVID-19 vaccine JANSSEN (AD26.COV2.S):

2 deaths and 33 injuries up to 20/03/2021

(Not enough data yet to make a graph)

  • 4 Cardiac disorders incl. 1 death
  • 1 Ear and labyrinth disease
  • 2 Eye disorders
  • 5 Gastrointestinal disorders incl. 1 death
  • 21 General disorders and administration site conditions
  • 3 Infections and infestations
  • 1 Injury, poisoning and procedural complications
  • 7 Investigations
  • 3 Musculoskeletal and connective tissue disorders
  • 19 Nervous system disorders
  • 36 Pregnancy, postpartum and perinatal disorders
  • 17 Product Problems
  • 2 Psychiatric disorders
  • 1 Reproductive system and breast disorders
  • 6 Respiratory, thoracic and mediastinal disorders
  • 4 Skin and subcutaneous tissue disorders

 

 

This is public information funded by the European Medicines Agency (EMA) and anyone can use the EudraVigilance system and verify this data.

These are serious figures, and yet we don't know of any news organization that has published anything about this, except Health Impact News & Frontnieuws.

Please share this information far and wide, and feel free to copy and republish anything in this article.

 

Here's what EudraVigilance says of their database:

This website was launched by the European Medicines Agency in 2012 to provide public access to reports of suspected side effects (also known as suspected side effects of medicines). These reports are submitted electronically to EudraVigilance by national medicines regulatory authorities and by pharmaceutical companies that hold marketing authorizations (licenses) for the medicines.

EudraVigilance is a system for collecting reports of suspected side effects. These reports are used to assess the benefits and risks of medicines during their development and to monitor their safety after their authorization in the European Economic Area (EEA). EudraVigilance has been in use since December 2001.

This website has been set up to comply with the EudraVigilance Access Policy, which is designed to improve public health by supporting the surveillance of the safety of medicines and to increase transparency for stakeholders, including the general public.

The Management Board of the European Medicines Agency first approved the EudraVigilance Access Policy in December 2010. In December 2015, the Management Board approved a revision based on the 2010 pharmacovigilance legislation. give regulatory authorities in the EEA, the European Commission, healthcare professionals, patients and consumers, as well as the pharmaceutical industry and research organizations, access to reports on suspected adverse reactions.

Transparency is an important guiding principle of the Office and is crucial for building confidence in the regulatory process. By increasing transparency, the Office can better respond to the growing need of stakeholders, including the general public, for access to information. (Bron)

5 20 To vote
Article review
Subscribe now
Subscribe to
guest
May be your real name or a pseudonym
Not required
11 comments
eldest
newest most voted
Inline feedback
See all comments
CommonSenseTV
Dutch NL English EN French FR German DE Spanish ES
11
0
What is your response to this?x
()
x